8-K: HeartSciences Reports Q2 2026 Results, Advances AI-ECG Platform

HeartSciences reported no meaningful revenue for fiscal Q2 2026, while making progress on its MyoVista Insights platform and submitting its wavECG device to the FDA.

Summary

• Reported financial results for the fiscal second quarter ended October 31, 2025 (FQ2 2026).
• No meaningful revenue was reported for FQ2 2026.
• Cash and cash equivalents were approximately $2.0 million as of October 31, 2025.
• Shareholders' equity stood at $4.2 million as of October 31, 2025.
• Significant progress was made in the commercialization of the MyoVista Insights healthcare IT platform.
• The MyoVista wavECG device was submitted to the U.S. Food and Drug Administration (FDA) for 510(k) premarket clearance.
• MyoVista Insights is classified as a Medical Device Data System (MDDS), which is exempt from 510(k) clearance, leading to expected lower organizational costs and faster commercial rollout.
• MyoVista Insights has received strong validation from early adopters since its launch in May 2025 and the recent release of Version 1.1.
• The company is actively engaged in commercial discussions with several healthcare institutions for MyoVista Insights deployment.
• MyoVista Insights is designed as a platform to host third-party AI-ECG algorithms through an AI-ECG marketplace, with discussions ongoing with potential partners.
• FDA submissions for the MyoVista wavECG device and its impaired cardiac relaxation AI-ECG software algorithm were separated following updated guidelines by the American Society of Echocardiography (ASE) for Left Ventricular Diastolic Dysfunction (LVDD).

Sentiment

Score: 4

Explanation: The company reported no meaningful revenue and has limited cash, which are significant concerns. However, it has made substantial progress in product commercialization (MyoVista Insights) and regulatory milestones (FDA submission for MyoVista wavECG). The strategic approach with MDDS classification and an AI-ECG marketplace offers potential for future growth, balancing the current financial weaknesses with future prospects.

Positives

• MyoVista Insights, classified as a Medical Device Data System (MDDS), benefits from significantly lower regulatory requirements and 510(k) clearance exemption, which is expected to result in substantially lower organizational costs and a faster commercial rollout.
• The MyoVista Insights platform has received strong validation from early adopters since its launch in May 2025 and the recent Version 1.1 release.
• The company is actively engaged in commercial discussions with several healthcare institutions for MyoVista Insights deployment and expects to announce multiple key customer wins in the near term.
• MyoVista Insights is strategically designed as a platform capable of hosting third-party FDA-cleared AI-ECG algorithms through an AI-ECG marketplace, positioning the company to capture a multibillion-dollar market opportunity while reducing algorithm development and regulatory clearance costs and time.
• The submission of the MyoVista wavECG device to the FDA for 510(k) premarket clearance represents an important regulatory milestone and advances the company's strategy to modernize ECG through artificial intelligence.

Negatives

• No meaningful revenue was reported for FQ2 2026, indicating a lack of significant commercial sales during the quarter.
• Cash and cash equivalents of approximately $2.0 million as of October 31, 2025, are relatively low for a company in the commercialization phase, potentially raising concerns about liquidity and operational runway without future revenue generation or capital.

Risks

• Forward-looking statements are subject to significant assumptions, risks, and uncertainties, including future economic, competitive, and market conditions, and future business decisions, many of which are difficult or impossible to predict accurately and are beyond the Company's control.
• The expectations reflected in forward-looking statements involve significant assumptions, risks, and uncertainties, and these expectations may prove to be incorrect.
• Investors should not place undue reliance on forward-looking statements, which speak only as of the date of the press release.

Future Outlook

The company expects to announce multiple key customer wins for MyoVista Insights in the near term. Management believes the MyoVista Insights platform uniquely positions HeartSciences to capture a multibillion-dollar market opportunity while significantly reducing the cost and time required for algorithm development and regulatory clearance. An investor call is planned for early in the new year to demonstrate the MyoVista Insights software and provide additional details regarding its commercialization strategy and market opportunity.

Management Comments

• "MyoVista Insights is a state-of-the-art ECG reporting and management platform that delivers meaningful clinical, operational, and data security benefits for healthcare systems." Andrew Simpson, Chief Executive Officer of HeartSciences.
• "In a short period of time, we have received strong validation from early adopters and are actively engaged in commercial discussions with several healthcare institutions. We expect to announce key customer wins in the near term." Andrew Simpson, Chief Executive Officer of HeartSciences.
• "The submission of the MyoVista wavECG device to the FDA represents an important regulatory milestone for the Company and advances our broader strategy to modernize ECG through artificial intelligence." Andrew Simpson, Chief Executive Officer of HeartSciences.

Industry Context

HeartSciences operates within the healthcare information technology (HIT) sector, focusing on integrating artificial intelligence (AI) into electrocardiography (ECG). The strategic classification of MyoVista Insights as a Medical Device Data System (MDDS) and its design to host third-party AI-ECG algorithms aligns with broader industry trends towards AI-driven diagnostics, streamlined regulatory pathways, and platform-based solutions. The company's adaptation to updated American Society of Echocardiography (ASE) guidelines for Left Ventricular Diastolic Dysfunction (LVDD) also reflects responsiveness to evolving clinical standards in cardiac diagnostics.

Stakeholder Impact

• Shareholders face potential for future value creation if commercialization efforts succeed and FDA clearance is obtained, but current lack of revenue and limited cash pose risks to short-term performance.
• Customers (healthcare institutions) stand to benefit from MyoVista Insights' clinical, operational, and data security features, and potential access to an AI-ECG marketplace.
• Employees may see continued employment and potential growth opportunities as the company expands its commercial footprint.
• Regulatory authorities, specifically the FDA, are actively engaged in the 510(k) clearance process for the MyoVista wavECG device.

Next Steps

• Announce multiple key customer wins for MyoVista Insights in the near term.
• Host an investor call early in the new year to demonstrate the MyoVista Insights software and provide additional details regarding commercialization strategy and market opportunity.
• Continue discussions with partners to host FDA-cleared AI-ECG algorithms on the MyoVista Insights platform.
• Await FDA 510(k) premarket clearance for the MyoVista wavECG device.

Key Dates

Recommendation

The company is in a critical transition phase from development to commercialization. While the lack of revenue and limited cash are concerning, the strategic progress with MyoVista Insights (MDDS classification, early adopter validation, commercial discussions) and the FDA submission for MyoVista wavECG represent significant milestones. The potential for a multi-billion dollar market opportunity through its AI-ECG marketplace is compelling. However, the execution risk remains high until meaningful revenue generation and customer wins are secured. A 'Hold' recommendation allows investors to observe the outcome of these commercialization efforts and regulatory clearances before making further investment decisions.

Keywords

Healthcare IT, AI, Artificial Intelligence, ECG, EKG, MyoVista Insights, MyoVista wavECG, Medical Device Data System, MDDS, FDA 510(k), Cardiac Relaxation, LVDD, HeartSciences, HSCS